Citigroup Inc Provention Bio, Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$6.7 - $24.21 $104,325 - $376,973	15,571 Added 154.97%	25,619 $617,000
Q4 2022 Feb 09, 2023	BUY	$4.52 - $10.57 $31,454 - $73,556	6,959 Added 225.28%	10,048 $106,000
Q3 2022 Nov 10, 2022	SELL	$3.43 - $5.62 $10,701 - $17,534	-3,120 Reduced 50.25%	3,089 $14,000
Q2 2022 Aug 10, 2022	SELL	$3.65 - $7.3 $19,111 - $38,222	-5,236 Reduced 45.75%	6,209 $24,000
Q1 2022 May 12, 2022	SELL	$3.4 - $7.88 $23,827 - $55,223	-7,008 Reduced 37.98%	11,445 $84,000
Q4 2021 Feb 10, 2022	SELL	$5.59 - $7.39 $191,820 - $253,587	-34,315 Reduced 65.03%	18,453 $104,000
Q3 2021 Nov 10, 2021	BUY	$5.66 - $8.33 $298,666 - $439,557	52,768 New	52,768 $338,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.